Carcinoma, Non-Small-Cell Lung: all 6,641 studies

Page 12 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.

• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 2
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsRecruitingNCT06171750Phase 1
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Phase 3
• An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyRecruitingNCT06169956
• Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.RecruitingNCT06167460
• [68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung CancerRecruitingNCT06165874Not applicable
• Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence.RecruitingNCT06163846
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingNCT06162221Phase 1/2
• To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06154967Not applicable
• A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesRecruitingNCT06150664Phase 1
• A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerRecruitingNCT06147570Phase 2
• A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk FactorsNot yet recruitingNCT06143735Phase 2
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Addition of Hypofractionated High Dose Radiation in Oligometastatic DiseaseRecruitingNCT06141070Phase 3
• Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced MyelosuppressionNot yet recruitingNCT06140082
• Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation TherapyRecruitingNCT06139627Not applicable
• Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung CancerRecruitingNCT06136910Phase 1/2
• A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsRecruitingNCT06131840Phase 1
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/2
• K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C MutationRecruitingNCT06127940Phase 1
• Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLCNot yet recruitingNCT06127329Not applicable
• Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLCRecruitingNCT06127303Phase 2
• Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLCRecruitingNCT06123754Phase 3
• A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung CancerRecruitingNCT06122064Not applicable
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3
• A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC PatientsRecruitingNCT06118229
• The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLCNot yet recruitingNCT06117644
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06116682Phase 2
• QOL After SURGERY and ADJUVANT TreatmentNot yet recruitingNCT06115239
• Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer PatientsRecruitingNCT06114108Not applicable
• A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingNCT06110663Phase 3
• The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCRecruitingNCT06109558Phase 1/2
• Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical SurgeryRecruitingNCT06109454
• Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT06109402Phase 2
• A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung CancerRecruitingNCT06108726Phase 2
• Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint InhibitorsRecruitingNCT06107608Not applicable
• Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAGRecruitingNCT06107374Phase 2
• LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)RecruitingNCT06103682Not applicable
• A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R MutationRecruitingNCT06102928Not applicable
• PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLCRecruitingNCT06102057Phase 2
• Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI TreatmentRecruitingNCT06095934Not applicable
• Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCRecruitingNCT06092086Phase 2
• Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCRecruitingNCT06088771Phase 1/2
• Test-retest Evaluation of [18F]F-AraG PETRecruitingNCT06084806Phase 2
• An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLCRecruitingNCT06083870Phase 1
• The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer PatientsRecruitingNCT06082492Not applicable
• Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung CancerRecruitingNCT06081777
• SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR MutationsRecruitingNCT06080776Phase 3
• Confocal Laser Endomicroscopy VERificationRecruitingNCT06079970Not applicable
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2
• Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone MetastasesRecruitingNCT06069570Phase 1
• Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)Not yet recruitingNCT06068088
• OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainRecruitingNCT06068049
• Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell CancerNot yet recruitingNCT06067776Phase 1
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung CancerRecruitingNCT06065813Phase 2
• Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom ManagementNot yet recruitingNCT06060964Early Phase 1
• Safety and Efficacy of OBX-115 in Advanced Solid TumorsRecruitingNCT06060613Phase 1/2
• Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung CancerRecruitingNCT06057766Not applicable
• Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsNot yet recruitingNCT06054191Phase 2
• A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)RecruitingNCT06053099Not applicable
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionRecruitingNCT06051695Phase 1/2
• Phase I Study of HSK40118 in NSCLC Patients With EGFR MutationRecruitingNCT06050980Phase 1
• Prospective Evaluation of Single Cell Mutations in a Panel of Known Oncogenes in NSCLC Surgical SpecimensRecruitingNCT06050278
• A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung CancerRecruitingNCT06047860Phase 2
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/2
• A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerRecruitingNCT06046495Phase 1
• Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingNCT06043973Phase 3
• First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsRecruitingNCT06043817Phase 1/2
• T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingNCT06043713Phase 1
• Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsRecruitingNCT06041776Phase 3
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingNCT06040541Phase 1
• Using Urine Samples to Identify Lung CancerRecruitingNCT06033248
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
• Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNot yet recruitingNCT06031597Phase 3
• Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsNot yet recruitingNCT06029816Phase 2
• Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2
• Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled StudyEnrolling by invitationNCT06028412Not applicable
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingNCT06026410Phase 1
• Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingNCT06020989Phase 2
• Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and ChemotherapyRecruitingNCT06020430Not applicable
• Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruitingNCT06015568Phase 1
• A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCRecruitingNCT06010329Phase 2
• Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)Not yet recruitingNCT05998993Not applicable
• Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLCRecruitingNCT05997719
• IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCRecruitingNCT05994131Phase 1/2
• Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung CancerRecruitingNCT05991895
• A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLCRecruitingNCT05991206
• A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung CancerRecruitingNCT05991193
• Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung CancerRecruitingNCT05990946Not applicable
• A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Phase 3
• A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)RecruitingNCT05989542Phase 3
• Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and DabrafenibNot yet recruitingNCT05988697
• Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCRecruitingNCT05987826Phase 2
• Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung CancerRecruitingNCT05987345Not applicable
• Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsRecruitingNCT05985655Phase 1/2
• Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung CancerRecruitingNCT05985330
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingNCT05983432Phase 1
• Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerRecruitingNCT05979818Phase 1

← Carcinoma, Non-Small-Cell Lung overview